Chronic hepatitis B: Immunological profile and current therapeutic vaccines in clinical trials (Q38738344)

6 September 2017

Chronic hepatitis B: Immunological profile and current therapeutic vaccines in clinical trials (English)

1 reference

6 September 2017

1 reference

1 reference

1 reference

1 reference

Yadira Lobaina

1

1 reference

6 September 2017

Marie-Louise Michel

series ordinal

2

1 reference

6 September 2017

language of work or name

English

0 references

publication date

25 March 2017

1 reference

6 September 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

6 September 2017

35

1 reference

6 September 2017

2308-2314

1 reference

6 September 2017

18

1 reference

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.

6 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

The immune tolerant phase of chronic HBV infection: new perspectives on an old concept

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Current status of antiviral therapy for hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Trained immunity in newborn infants of HBV-infected mothers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Occult hepatitis B infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Genomic analysis of the host response to hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Effects of interferon-α/β on HBV replication determined by viral load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Living in the liver: hepatic infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Translation of immunological knowledge into better treatments of chronic hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Regulatory T cells are the most important determinant factor of hepatitis B infection prognosis: a systematic review and meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

The enigma of concurrent hepatitis B surface antigen (HBsAg) and antibodies to HBsAg.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Decreased numbers and impaired function of circulating dendritic cell subsets in patients with chronic hepatitis B infection (R2)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

NK cells: a double-edged sword in chronic hepatitis B virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Natural killer cells in hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Responses to multiple injections with alum alone compared to injections with alum adsorbed to proteins in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Hepatitis: Long-term therapy of chronic hepatitis B reverses cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

A hepatitis B vaccine with a novel adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

The two-component adjuvant IC31® boosts type i interferon production of human monocyte-derived dendritic cells via ligation of endosomal TLRs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Novel targets for hepatitis B virus therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Search for a cure for chronic hepatitis B infection: How close are we?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Discontinuation of oral antivirals in chronic hepatitis B: A systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.049

10.1016/J.VACCINE.2017.03.049

7 January 2021

Identifiers

DOI

1 reference

release_3ugf75o7wng2vfqtlkzw2xh53y

6 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3ugf75o7wng2vfqtlkzw2xh53y

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference